Shopping Cart
- Remove All
- Your shopping cart is currently empty
ARD-2585 is an orally active and selective androgen receptor PROTAC degrader with anticancer activity for the study of prostate cancer.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $333 | Backorder | |
5 mg | $795 | Backorder | |
10 mg | $1,280 | Backorder | |
25 mg | $2,530 | Backorder | |
50 mg | $3,970 | Backorder |
Description | ARD-2585 is an orally active and selective androgen receptor PROTAC degrader with anticancer activity for the study of prostate cancer. |
Targets&IC50 | VCaP cell:1.5 nM, LNCaP AR+ cell:16.2 nM |
In vitro | ARD-2585 is effective in reducing the AR protein level at the 3 and 24 h time-points by 78% and 60% at the 6 h time-point. ARD-2585 achieves picomolar DC50 values and >98% of Dmax in the VCaP cell line with a wild-type AR and in the LNCaP cell line carrying a T878A-mutated AR mutant. ARD-2585 potently inhibits cell growth with IC50 values of 1.5 nM and 16.2 nM in the VCaP and LNCaP AR+ prostate cancer cell lines. [1] |
In vivo | At the end of the treatment (day 37), 20 and 40 mg/kg ARD-2585 inhibits tumor growth by 54.9, 74.3, and 65.9%. ARD-2585 effectively reduces AR protein the VCaP xenograft tumor tissue in mice and inhibits VCaP tumor growth. [1] |
Alias | ARD2585 |
Molecular Weight | 763.28 |
Formula | C41H43ClN8O5 |
Cas No. | 2757422-79-8 |
Storage | keep away from direct sunlight | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 80 mg/mL(104.81 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.